The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M

Podobné jednotky

• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  Autor: Tseng, Jeng-Sen, a další
  Vydáno: (2016)
• Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
  Autor: Su, Kang-Yi, a další
  Vydáno: (2018)
• Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
  Autor: Tseng, Jeng-Sen, a další
  Vydáno: (2018)
• ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
  Autor: Chang, Gee-Chen, a další
  Vydáno: (2020)
• The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
  Autor: Huang, Yen-Hsiang, a další
  Vydáno: (2018)